rs1800565
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM5BP4_Moderate
The NM_000256.3(MYBPC3):c.1961G>A(p.Arg654His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,722 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R654C) has been classified as Pathogenic.
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.1961G>A | p.Arg654His | missense_variant | 21/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.1961G>A | p.Arg654His | missense_variant | 21/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.1961G>A | p.Arg654His | missense_variant | 20/34 | 5 | ENSP00000382193.2 | |||
MYBPC3 | ENST00000544791.1 | n.1961G>A | non_coding_transcript_exon_variant | 21/27 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152188Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000241 AC: 6AN: 249152Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135178
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461534Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727022
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152188Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74348
ClinVar
Submissions by phenotype
Cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 23, 2023 | This missense variant replaces arginine with histidine at codon 654 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). In vitro functional studies have shown that this variant is likely to affect intramolecular interactions (PMID: 12386147, 12787675). This variant has been reported in an individual affected with hypertrophic cardiomyopathy and in his three asymptomatic relatives (PMID: 9541115, 11447480). This variant has been identified in 6/249152 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Aug 24, 2017 | - - |
Hypertrophic cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Dec 01, 2023 | This missense variant replaces arginine with histidine at codon 654 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). In vitro functional studies have shown that this variant is likely to affect intramolecular interactions (PMID: 12386147, 12787675). This variant has been reported in an individual affected with hypertrophic cardiomyopathy and in his three asymptomatic offsprings (PMID: 9541115, 11447480). This variant has also been identified in 6/249152 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 07, 2022 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 654 of the MYBPC3 protein (p.Arg654His). This variant is present in population databases (rs1800565, gnomAD 0.02%). This missense change has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 9541115). ClinVar contains an entry for this variant (Variation ID: 42588). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects MYBPC3 function (PMID: 12386147). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 29, 2019 | The p.Arg654His variant in MYBPC3 has been reported in 1 individual with HCM (Moolman-Smook 1998) and 0.016% (3/17976) East Asian chromosomes by gnomAD. Functional studies suggest that this variant may impact the protein; though, it is not clear whether this would result in disease (Moolman-Smook 1998, Idowu 2003). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of this variant is uncertain. ACMG/AMP Criteria applied: None. - |
Left ventricular noncompaction 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jun 24, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as VUS-3C. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with hypertrophic cardiomyopathy 4 (HCM; MIM#115197), left ventricular noncompaction 10 (MIM#615396) and dilated cardiomyopathy 1MM (MIM#615396) however, the ClinGen expert panel have assessed gene-disease association with DCM as limited. (I) 0108 - This gene is associated with both recessive and dominant disease. Dominant inheritance is frequently reported in adult onset conditions, however, recessive inheritance results in a more severe early-onset phenotype (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity in HCM (PMID: 32841044). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to histidine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 (v2: 6 heterozygotes, 0 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2: 5 heterozygotes, 0 homozygotes). (I) 0503 - Missense variant consistently predicted to be tolerated by multiple in silico tools or not conserved in placental mammals with a minor amino acid change. (SB) 0600 - Variant is located in the annotated C5 domain (PMID: 12386147). (I) 0705 - No comparable missense variants have previous evidence for pathogenicity. Alternative changes to cysteine and glycine at the same amino acid residue have been reported in individuals with HCM or DCM, and also as VUS (ClinVar, PMIDs: 27532257, 21750094, 30984009, 25351510). However, both are more major amino acid changes. (I) 0808 - Previous reports of pathogenicity for this variant are conflicting. It has been reported as heterozygous in individuals with HCM (PMIDs: 9541115, 25132132) and also as VUS (ClinVar). (I) 1010 - Functional evidence for this variant is inconclusive. An in vitro study showed the MYBPC3 protein domain C5 in R654H mutant had significantly weaker binding to domain C8-C10 compared with wild type (PMID: 12386147). Another study showed R654H protein had normal folding and stability (PMID: 12787675). (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Hypertrophic cardiomyopathy 4;C3715165:Left ventricular noncompaction 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 21, 2021 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 09, 2022 | The c.1961G>A (p.R654H) alteration is located in exon 21 (coding exon 21) of the MYBPC3 gene. This alteration results from a G to A substitution at nucleotide position 1961, causing the arginine (R) at amino acid position 654 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at